Hidalgo Medina, MD, PhD, Discusses the Use of Motixafortide/Pembrolizumab and FOLFIRI in PDAC
November 24, 2021

For Pancretic Cancer Awareness month, CancerNetwork® spoke with Manuel Hidalgo Medina, MD, PhD, about the importance of the phase 2 COMBAT/KEYNOTE-202 trial examining motixafortide and pembrolizumab plus nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic ductal adenocarcinoma.

First-Line Nivolumab/Ipilimumab Yields Impressive Treatment-Free Survival in Advanced Renal Cell Carcinoma
November 24, 2021

Patients with advanced renal cell carcinoma who received first-line nivolumab and ipilimumab experienced an improved treatment-free survival vs sunitinib.

Immune Checkpoint Inhibitors May Be Effective, Safe in Geriatric Cancer
November 24, 2021

Retrospective data suggest survival outcomes were positive and safety was reasonable for patients with cancer aged 80 years or older who received immune checkpoint inhibitors.

Amivantamab for the Treatment of EGFR Exon 20 Insertions in NSCLC
November 24, 2021

Zofia Piotrowska, MD, discusses the role of amivantamab in the treatment of patients with NSCLC and EGFR exon 20 insertions.

Exposure-Response Analysis Highlights Optimal Dosing for Lurbinectedin in SCLC
November 24, 2021

A exposure-response analysis indicated that a 3.2mg/m2 dose of lurbinectedin every 3 weeks achieved a favorable risk/benefit profile in patients with small cell lung cancer.

Historical Treatment Approach for EGFR Exon 20 Insertions in NSCLC
November 24, 2021

Zofia Piotrowska, MD, reviews historical treatment approaches for patients with NSCLC and EGFR exon 20 insertions.

Treatment Options for High-Volume mCNPC
November 24, 2021

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

Selecting Therapy to Manage Steroid-Refractory Chronic GVHD
November 24, 2021

Considerations regarding treatment selection for patients with steroid-refractory chronic graft-vs-host disease based on current unmet needs and newer therapies in the pipeline.

Pharmacotherapy for Myelofibrosis
November 24, 2021

Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.

Case 2: Treatment Decisions for a Patient With Chronic GVHD
November 24, 2021

Reactions to a case of chronic graft-vs-host disease and thoughts on sequencing therapy.